Biosensors

Biosensors: received approval from the Department of Health in Taiwan for sale of its BioMatrix drug-eluting stent system in Taiwan. CEO, Jeffrey B Jump commented that Taiwan is “an important regional market with a high rate of coronary stent usage”. Stock trades at 20.2x historical PE. Nomura rated Buy with $1.20 target last month.